The Molecular Clinical Trials Shared Resource (MCTSR) is a highly-specialized resource that provides expert advice and technological and experimental support for the conduct of molecular assays of drug targets and drug activity within prospective clinical trials. The MCTSR, collects, processes and analyzes samples from patients treated within prospective clinical trials of molecular targeted therapies. Resource support extends throughout the entire research process from initial study design and planning through to the implementation and interpretation of results. The MCTSR is currently supporting 17 clinical trials within the SJCCC and cooperative groups and is engaging all four SJCCC programs that treat patients. During the current reporting period the resource provided molecular biology services to papers reporting seven Phase I clinical trials and five Phase II studies, of which seven were published in the Journal of Clinical Oncology. The resource contributed major molecular biology services to a further nine papers, including studies published in Nature, Nature Medicine, and Cancer Cell.

Public Health Relevance

The Molecular Clinical Trials Shared Resource provides Center members with access to laboratory research expertise for the conduct of assays of drug target expression and activity in the context of prospective clinical trials. Consequently, the MCTSR has stimulated and facilitated interactions between clinical and laboratory based researchers throughout the Cancer Center. PROJECT/PERFORMANCE SITE(S) (if additional space is needed, use Project

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
St. Jude Children's Research Hospital
United States
Zip Code
Ganguly, Samit; Panetta, John C; Roberts, Jessica K et al. (2018) Ketamine Pharmacokinetics and Pharmacodynamics Are Altered by P-Glycoprotein and Breast Cancer Resistance Protein Efflux Transporters in Mice. Drug Metab Dispos 46:1014-1022
Pinto, Emilia M; Hamideh, Dima; Bahrami, Armita et al. (2018) Malignant rhabdoid tumors originating within and outside the central nervous system are clinically and molecularly heterogeneous. Acta Neuropathol 136:315-326
Upadhyaya, Santhosh A; McGee, Rose B; Wilky, Breelyn A et al. (2018) Malignant progression of a peripheral nerve sheath tumor in the setting of rhabdoid tumor predisposition syndrome. Pediatr Blood Cancer 65:e27030
Schulte, Fiona; Brinkman, Tara M; Li, Chenghong et al. (2018) Social adjustment in adolescent survivors of pediatric central nervous system tumors: A report from the Childhood Cancer Survivor Study. Cancer 124:3596-3608
Wu, Gang; Fan, Liying; Edmonson, Michael N et al. (2018) Inhibition of SF3B1 by molecules targeting the spliceosome results in massive aberrant exon skipping. RNA 24:1056-1066
Coustan-Smith, Elaine; Song, Guangchun; Shurtleff, Sheila et al. (2018) Universal monitoring of minimal residual disease in acute myeloid leukemia. JCI Insight 3:
Walker, Breya; Conklin, Heather M; Anghelescu, Doralina L et al. (2018) Parent perspectives and preferences for strategies regarding nonsedated MRI scans in a pediatric oncology population. Support Care Cancer 26:1815-1824
Hanna, Jason A; Garcia, Matthew R; Lardennois, Alicia et al. (2018) PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma. Oncogene 37:1991-2007
Klosky, James L; Lehmann, Vicky; Flynn, Jessica S et al. (2018) Patient factors associated with sperm cryopreservation among at-risk adolescents newly diagnosed with cancer. Cancer 124:3567-3575
Gibson, Todd M; Mostoufi-Moab, Sogol; Stratton, Kayla L et al. (2018) Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970-99: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol 19:1590-1601

Showing the most recent 10 out of 6764 publications